SCHEMBL2539705

SCHEMBL2539705

COc1cc(Cl)nc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.62
LMNA P02545 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
ALDH1A1 P00352 5/20 0.58
MAPT P10636 4/20 0.58
POLB P06746 4/20 0.58
ALOX15 P16050 1/20 0.58
IGF1R P08069 1/20 0.56
KDM4E B2RXH2 4/20 0.55
HTT P42858 2/20 0.55
NPC1 O15118 2/20 0.55
NQO2 P16083 2/20 0.50
SLC2A1 P11166 1/20 0.50
RAD52 P43351 1/20 0.46
ACACA Q13085 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28598438 0.98 HPGD (0.60) HPGDLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL27508841 0.85 KDM4E (0.50) HPGDLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL3965450 0.81 KDM4E (0.47) HPGDLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL7810731 0.81 NCF1 (0.51) HPGDLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL2533905 0.80 IGF1R (0.51) HPGDSMN1; SMN2ALDH1A1MAPTPOLB
SCHEMBL10512737 0.80 MAPT (0.52) HPGDLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL29877118 0.79 LMNA (0.64) HPGDLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL30065410 0.79 HPGD (0.64) HPGDLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL28010962 0.79 LMNA (0.64) HPGDLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL266444 0.79 LMNA (0.64) HPGDLMNASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113201028-B Methoxy-regulation-based broadband yellow phosphorescent 2-phenylquinoline iridium (III) complex and preparation method and application thereof 南京邮电大学 2022-12-09 CN claimed
CN-113201028-A Methoxy-regulation-based broadband yellow phosphorescent 2-phenylquinoline iridium (III) complex and preparation method and application thereof 南京邮电大学 2021-08-03 CN claimed
CN-113201028-B Methoxy-regulation-based broadband yellow phosphorescent 2-phenylquinoline iridium (III) complex and preparation method and application thereof 南京邮电大学 2022-12-09 CN disclosed
CN-113201028-A Methoxy-regulation-based broadband yellow phosphorescent 2-phenylquinoline iridium (III) complex and preparation method and application thereof 南京邮电大学 2021-08-03 CN disclosed
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 US disclosed
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
EP-2003131-A1 AMINOPYRROLIDINE COMPOUND Taisho Pharmaceutical Co. Ltd. (JP) 2008-12-17 EP disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2003040103-A1 β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) BRISTOL-MYERS SQUIBB COMPANY (US) 2003-05-15 WO disclosed
WO-2002026713-A1 ANTIPARASITIC COMPOUNDS KING'S COLLEGE LONDON (GB) 2002-04-04 WO disclosed
US-6320051-B1 AMINO(NH) OR OXYGEN(O) SUBSTITUTED, ENZYME INHIBITORS OF STAPHLOCCOCUS AUREUS METHIONYL T-RNA SYNTHETASE (MRS); ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2001-11-20 US disclosed
CN-1307565-A Quinolones used as MRS inhibitor and bactericides SMITHKLINE BEECHAM PLC (GB) 2001-08-08 CN disclosed
EP-1084110-A1 QUINOLONES USED AS MRS INHIBITORS AND BACTERICIDES SMITHKLINE BEECHAM PLC (GB) 2001-03-21 EP disclosed
WO-1999055677-A1 QUINOLONES USED AS MRS INHIBITORS AND BACTERICIDES SMITHKLINE BEECHAM PLC (GB) 1999-11-04 WO disclosed
EP-0317188-B1 Heteroaromatic enamide derivatives and their use as pesticides ROUSSEL UCLAF (FR) 1995-09-27 EP disclosed
US-5114940-A Insecticides or anthelmintics from fused ring heterocycles containing amides or thioamides ROUSSEL-UCLAF (FR) 1992-05-19 US disclosed
EP-0317188-A2 Heteroaromatic enamide derivatives and their use as pesticides ROUSSEL UCLAF (FR) 1989-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 HPGD 478/4885LMNA 435/4885SMN1; SMN2 3011/4885
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND MC4R, MC5R, MC2R HPGD 2259/4885LMNA 4408/4885SMN1; SMN2 398/4885
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 HPGD 2310/4885LMNA 3391/4885SMN1; SMN2 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.